Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of AZD8233 in Healthy Males with Elevated LDL-C
NCT03593785Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2018
- Primary completion
- Dec 2020
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD8233 in hypercholesterolemia (5 cohorts), sponsored by AstraZeneca. Primary endpoints: Number of subjects with adverse events (AEs) due to AZD8233 SC SAD treatment, Vital sign: Blood pressure [BP] and 14 more. Started Aug 2018; status: completed.
02
Drugs
AZD8233
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT03593785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03593785.